In this article, we will examine in detail the concept of DCG-IV and its relevance in different contexts. It is essential to understand the importance of DCG-IV in our current society, as well as its influence on various aspects of daily life. Throughout this analysis, we will explore the implications and applications of DCG-IV in different areas, from culture and history to science and technology. Likewise, we will examine the impact of DCG-IV on contemporary society and its evolution over time. This article aims to provide a comprehensive and up-to-date view on DCG-IV, in order to foster a deeper understanding of its importance and contribution to society.
DCG-IV is a research drug which acts as a group-selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).[1] It has potent neuroprotective and anticonvulsant effects in animal studies,[2][3][4][5] as well as showing anti-Parkinsonian effects,[6][7] but also impairs the formation of memories.[8][9]
^Bruno V, Copani A, Battaglia G, Raffaele R, Shinozaki H, Nicoletti F (April 1994). "Protective effect of the metabotropic glutamate receptor agonist, DCG-IV, against excitotoxic neuronal death". European Journal of Pharmacology. 256 (1): 109–12. doi:10.1016/0014-2999(94)90624-6. PMID7517889.
^Yoshioka H, Sugita M, Kinouchi H (September 2009). "Neuroprotective effects of group II metabotropic glutamate receptor agonist DCG-IV on hippocampal neurons in transient forebrain ischemia". Neuroscience Letters. 461 (3): 266–70. doi:10.1016/j.neulet.2009.06.056. PMID19549561. S2CID23564621.
^Attwell PJ, Singh Kent N, Jane DE, Croucher MJ, Bradford HF (September 1998). "Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV)". Brain Research. 805 (1–2): 138–43. doi:10.1016/S0006-8993(98)00698-2. PMID9733953. S2CID10771399.
^Fei Z, Zhang X, Bai HM, Jiang XF, Wang XL (December 2006). "Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury". Journal of Clinical Neuroscience. 13 (10): 1023–7. doi:10.1016/j.jocn.2005.11.042. PMID17113985. S2CID6959171.
^Huang LQ, Rowan MJ, Anwyl R (February 1997). "mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD. induction, in the dentate gyrus in vitro". NeuroReport. 8 (3): 687–93. doi:10.1097/00001756-199702100-00022. PMID9106748. S2CID42513317.
^Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (February 2004). "Inhibitory effects of group II mGluR-related drugs on memory performance in mice". Physiology & Behavior. 80 (5): 747–58. doi:10.1016/j.physbeh.2003.12.010. PMID14984810. S2CID33433968.